Biotronik, an implantable medical device technology company, announced its first US implantation of the Amvia Edge pacemaker, which received US Food and Drug Administration approval in July.
The procedure was completed by Raul Weiss, MD, at Mount Sinai Medical Center in Miami, Fla.
Amvia Edge is Biotronik’s next-generation pacemaker family, featuring MRI Guard 24/7, an always-on MRI sensor. MRI Guard 24/7 is designed to allow a clinic to substantially reduce the time burden of device management for MRI scans by automatically recognizing when the patient enters an MRI field and converting the device to MRI mode. The device then automatically returns to its permanent programming following the completion of the scan, eliminating any pre- or post-scan programming needs.
“I was very pleased to have been a part of the first implant of Amvia Edge. The procedure went well, and I’m excited about the benefits this new device will be able to bring to our patients as well as our practice,” says Weiss in a release. “The ability to eliminate device scans before and after an MRI procedure is a much-needed advancement, and I look forward to seeing how these types of technologies help streamline our workflows in the future.”
Amvia Edge is the first pacemaker family from Biotronik to offer EarlyCheck, another tool designed to simplify clinic workflow by automating pre-discharge checks. EarlyCheck will automatically deliver a device report and IEGM to the Biotronik Home Monitoring Service Center two hours after implant, eliminating the need for an in-person device interrogation.
Additionally, Amvia Edge also offers Atrial ATP, providing multiple, automatic therapies in response to detected stable atrial arrhythmias, which may reduce atrial tachycardia burden and consequently help avoid atrial remodeling.
“I’m so pleased to hear about Dr Weiss and his team’s successful first implant of Amvia Edge,” says David Hayes, MD, chief medical officer at Biotronik, in a release. “This new family of devices was designed to optimize workflows and therapies to benefit patients and their care teams, as well as clinicians and staff.”
Photo caption: Biotronik’s Amvia Edge pacemaker
Photo credit: Biotronik